|
exercise |
10 |
|
fgf21 |
10 |
|
a-fabp |
7 |
|
blood–brain barrier |
7 |
|
ischaemic stroke |
7 |
|
jnk/c-jun signalling |
7 |
|
mmp-9 |
7 |
|
obesity |
7 |
|
diabetic cardiomyopathy |
6 |
|
mitochondrial dysfunction |
6 |
|
sirt3 |
6 |
|
autoimmune hypoglycaemia |
5 |
|
diagnosis |
5 |
|
elisa |
5 |
|
fibroblast growth factors |
5 |
|
insulin receptor autoantibodies |
5 |
|
type b insulin resistance |
5 |
|
adaptive thermogenesis |
4 |
|
adipocyte fatty acid binding protein |
4 |
|
adipocyte precursor cells |
4 |
|
adipokines |
4 |
|
adipose remodeling |
4 |
|
adipose tissue |
4 |
|
antibody drug candidate |
4 |
|
beiging |
4 |
|
eosinophils |
4 |
|
eotaxin |
4 |
|
fgfr1 |
4 |
|
ischemic stroke |
4 |
|
klb |
4 |
|
macrophages |
4 |
|
metabolic regulation |
4 |
|
neutralizing monoclonal antibody 6h2 |
4 |
|
pparγ |
4 |
|
type 2 immunity |
4 |
|
agonistic antibodies |
3 |
|
metabolic complications |
3 |
|
protein therapeutics |
3 |
|
case report |
2 |
|
cellular localization |
2 |
|
cyclic vomiting syndrome |
2 |
|
eias |
2 |
|
endothelial function |
2 |
|
exercise - physiological aspects |
2 |
|
exogenous insulin antibody syndrome |
2 |
|
fgf |
2 |
|
fibroblast growth factor 21 |
2 |
|
glycemic variability |
2 |
|
hla |
2 |
|
hypoglycaemia |
2 |
|
insulin antibodies |
2 |
|
metabolic syndrome x |
2 |
|
n-glycosylation |
2 |
|
nitric oxide |
2 |
|
non-alcoholic fatty liver disease |
2 |
|
nox1-nox4 |
2 |
|
obesity - complications |
2 |
|
protein stability |
2 |
|
proteomics |
2 |
|
reactive oxidative species |
2 |
|
sirtuin |
2 |
|
t2d |
2 |
|
type 1 diabetes |
2 |
|
β-klotho |
2 |
|
branched-chain amino acids |
1 |
|
fat deposition |
1 |
|
hepatic blood flow |
1 |
|
nonalcoholic steatohepatitis |
1 |
|
sd rats |
1 |
|
steatosis |
1 |
